A New England COVID-19 Registry of Patients With CNS Demyelinating Disease
A Pilot Analysis
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received February 13, 2021
- Accepted in final form June 1, 2021
- First Published August 2, 2021.
Author Disclosures
- Kelli M. Money, MD, PhD (kellimmoney{at}gmail.com),
- Ashmanie Mahatoo, MD (amahatoo{at}bidmc.harvard.edu),
- Soleil Samaan (ssamaan{at}bidmc.harvard.edu),
- Pria Anand, MD (pria2{at}bu.edu),
- Ursela Baber, MD (ubaber{at}bidmc.harvard.edu),
- Mary Bailey, MD (mary.bailey{at}trinityhealthofne.org),
- Rohit Bakshi, MD (rbakshi{at}bwh.harvard.edu),
- Andrew Bouley, MD (andrewbouley{at}elliotlewisms.org),
- Aaron Bower, MD (aaron.bower{at}yale.edu),
- Jonathan Cahill, MD (jcahill1{at}lifespan.org),
- Maria Houtchens, MD (mhoutchens{at}bwh.harvard.edu),
- Joshua Katz, MD (joshuakatz{at}elliotlewisms.org),
- Ellen Lathi, MD (ellenlathi{at}elliotlewisms.org),
- Elle Levit, MD (elle.levit{at}yale.edu),
- Erin E. Longbrake, MD, PhD (erin.longbrake{at}yale.edu),
- Matthew McAdams, MD (matthew.t.mcadams{at}lahey.org),
- Salvatore Napoli, MD (snapoli{at}myneurodr.com),
- Pooja Raibagkar, MD (praibagkar86{at}gmail.com),
- Peter Wade, MD (pwade{at}trinityhealthofne.org) and
- Jacob A. Sloane, MD, PhD
- Kelli M. Money, MD, PhD (kellimmoney{at}gmail.com),
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Ashmanie Mahatoo, MD (amahatoo{at}bidmc.harvard.edu),
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Soleil Samaan (ssamaan{at}bidmc.harvard.edu),
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Pria Anand, MD (pria2{at}bu.edu),
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Ursela Baber, MD (ubaber{at}bidmc.harvard.edu),
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Mary Bailey, MD (mary.bailey{at}trinityhealthofne.org),
(1) EMD Serono (2) Bristol Meyers Squibb (3)
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1)Genentech (2) Bristol Meyers Squibb (3) Novartis (4) Biogen (5) EMD Serono (6) Genzyme (7) Teva
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Rohit Bakshi, MD (rbakshi{at}bwh.harvard.edu),
NONE
NONE
NONE
Dr. Bakshi serves as Editor-in-Chief of (1) the Journal of Neuroimaging
NONE
NONE
NONE
Dr. Bakshi has received consulting fees from (1) EMD Serono.
NONE
NONE
NONE
Dr. Bakshi has received research support from (1) EMD Serono and (2) Novartis, and (3) BMS/Celgene.
NONE
NONE
Dr. Bakshi has received research support from the (1) Department of Defense (W81XWH-18-1-0648 and W81XWH1910836), (2) National Multiple Sclerosis Society (RR 2005-A-13 and RG-1707-28586), (3) Water Cove foundation, (4) Race to Erase MS, and (4) NIH (1 R03 EB30831-01). Stock/Stock Options, Medical Equipment & Materials: Dr. Bakshi's spouse holds stock in (1) Biogen, Inc. 2012-present.
NONE
NONE
NONE
NONE
NONE
NONE
- Andrew Bouley, MD (andrewbouley{at}elliotlewisms.org),
Banner, EMD-Serono, and Genentech
NONE
Massachusetts Neurologic Association
NONE
NONE
NONE
NONE
NONE
Alexion, Biogen, EMD-Serono, and Genentech
NONE
NONE
EMD-Serono, Genentech, Novartis
PCORI
NONE
The National MS Society
NONE
NONE
NONE
NONE
NONE
NONE
- Aaron Bower, MD (aaron.bower{at}yale.edu),
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Jonathan Cahill, MD (jcahill1{at}lifespan.org),
NONE
NONE
NONE
NONE
NONE
(1) Clinical Neuroimmunology: Multiple Sclerosis and Related Disorders, 2nd edition. Humana Press - Springer Nature Switzerland. 2019.
NONE
NONE
NONE
NONE
NONE
(1) F. Hoffman-La Roche, Ltd.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Maria Houtchens, MD (mhoutchens{at}bwh.harvard.edu),
Served on a scientific advisory board for EMDSerono, Biogen Idec, Teva Neuroscience, Roche Genentech, Sanofi Genzyme, Greenwich bioscience
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Compensated non-promotional journal club presentations and slide deck preparations: Novartis (2010), Serono (2019, 2020)
NONE
Sanofi Genzyme (investigator-initiated research funding) Biogen (investigator-initiated research funding) Serono (collaborative agreement research funding)
CDC consultant on subject of guidelines for contraception for MS patients (2015)
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Joshua Katz, MD (joshuakatz{at}elliotlewisms.org),
I am on the EMD-Serono Mavenclad steering committee
NONE
NONE
NONE
NONE
NONE
NONE
NONE
I am on the speakers bureau for Biogen, Genentech, EMD-Serono, Sanofi- Genzyme, and Novartis.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Ellen Lathi, MD (ellenlathi{at}elliotlewisms.org),
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Elle Levit, MD (elle.levit{at}yale.edu),
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Erin E. Longbrake, MD, PhD (erin.longbrake{at}yale.edu),
(1) Alexion (2) Genzyme (3) Genentech (4) EMD Serono (5) Biogen
NONE
NONE
(1) Neurology: Neuroimmunology & Neuroinflammation, editorial board member, 2020-present
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) Yale University received a 2-year grant from Genentech to support fellowship training (for 2020-2022). (2) MN39159 Clinical Trial, Genentech (3) ML42790 clinical trial (investigator initiated study with Genentech; global PI).
(1) NIH/NINDS K23 NS107624, PI, 2019-2024
NONE
(1) Race to Erase MS
NONE
NONE
NONE
NONE
NONE
NONE
- Matthew McAdams, MD (matthew.t.mcadams{at}lahey.org),
Genentech Fellow Advisory Board
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Salvatore Napoli, MD (snapoli{at}myneurodr.com),
NONE
NONE
speaker training; biogen, Genzyme, serono, Bristol myers
NONE
NONE
NONE
NONE
Biogen, Serono, Bristol Myers, Genzyme
Biogen, Serono, Bristol Myers, Genzyme, Genetech
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Pooja Raibagkar, MD (praibagkar86{at}gmail.com),
NONE
NONE
NONE
Journal editor, Research Journal of Neurology and Neuro Disorders, RAFT Publications, 2021
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Peter Wade, MD (pwade{at}trinityhealthofne.org) and
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1)Biogen, (2)Genetech, (3)Novartis, (4)BMS, (5)EMD/Serono, (6)Sanofi/Genzyme, (7)Mallinckrodt
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Jacob A. Sloane, MD, PhD
(1) Biogen (2) Teva (3) Genzyme (4) Roche
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- From the Department of Neurology (K.M.M., A.M., S.S., U.B., J.A.S.), Beth Israel Deaconess Medical Center, Boston; Department of Neurology (P.A.), Boston University School of Medicine, MA; The Mandell Comprehensive MS Center (M.B., P.W.), Hartford, CT; Department of Neurology (R.B., M.H.), Brigham and Women's Hospital, Boston; The Elliot Lewis Center (A. Bouley, J.K., E. Lathi), Wellesley, MA; Department of Neurology (A. Bower, E. Levit, E.E.L.), Yale School of Medicine, New Haven, CT; Department of Neurology (J.C.), Alpert Medical School of Brown University, Providence, RI; Department of Neurology (M.M.), Lahey Hospital, Burlington; Neurology Center of New England (S.N.), Foxboro, MA; and Department of Neurology (P.R.), Concord Hospital, Concord, NH.
- Correspondence
Dr. Sloane jsloane{at}bidmc.harvard.edu
Article usage
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Hastening the Diagnosis of Amyotrophic Lateral Sclerosis
Dr. Brian Callaghan and Dr. Kellen Quigg
► Watch
Related Articles
- No related articles found.
Topics Discussed
Alert Me
Recommended articles
-
Article
Incidence and Impact of COVID-19 in MSA Survey From a Barcelona MS UnitMaria Sepúlveda, Sara Llufriu, Eugenia Martínez-Hernández et al.Neurology: Neuroimmunology & Neuroinflammation, January 27, 2021 -
Article
COVID-19 in Patients With Neuromyelitis Optica Spectrum Disorders and Myelin Oligodendrocyte Glycoprotein Antibody Disease in North AmericaFrom the COViMS RegistryScott D. Newsome, Anne H. Cross, Robert J. Fox et al.Neurology: Neuroimmunology & Neuroinflammation, August 24, 2021 -
Article
COVID-19 outcomes in MSObservational study of early experience from NYU Multiple Sclerosis Comprehensive Care CenterErica Parrotta, Ilya Kister, Leigh Charvet et al.Neurology: Neuroimmunology & Neuroinflammation, July 09, 2020 -
Article
Impact of Coronavirus Disease 2019 in a French Cohort of Myasthenia GravisGuilhem Solé, Stéphane Mathis, Diane Friedman et al.Neurology, February 10, 2021